Menus for Managing Patients with Cutaneous T-cell Lymphoma

Overview

Journal Semin Cutan Med Surg

Specialties Dermatology
General Surgery

Date 2012 Feb 25

PMID 22361286

Authors

Brian Poligone

Peter Heald

Affiliations

Soon will be listed here.

Abstract

In the management of patients with cutaneous T-cell lymphoma (CTCL), there are numerous distinct therapy options. Each of these therapies is discussed in terms of when to use it, what factors limit the success of the treatment, and what to expect. A menu is defined as a list of items from which to choose. The treatments for CTCL are presented in various menus where they are options for a particular goal in a particular setting of CTCL. The best recognized clinical scenarios of CTCL are those recognized by the staging system: limited patch plaque (T1), disseminated patch plaque (T2), erythroderma (T4), and tumor (T3). Each phase of the disease will have the menu of therapy options presented for a given goal of management.

References

Wiegleb Edstrom D, Hedblad M . Long-term follow-up of photodynamic therapy for mycosis fungoides. Acta Derm Venereol. 2008; 88(3):288-90. DOI: 10.2340/00015555-0409. View

OConnor O, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B . Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29(9):1182-9. PMC: 3083873. DOI: 10.1200/JCO.2010.29.9024. View

Dreno B, Godefroy W, Fleischmann M, Bureau B, LITOUX P . Low-dose recombinant interferon-alpha in the treatment of cutaneous T-cell lymphomas. Br J Dermatol. 1989; 121(4):543-4. DOI: 10.1111/j.1365-2133.1989.tb15526.x. View

Vonderheid E, Tan E, KANTOR A, Shrager L, Micaily B, VAN SCOTT E . Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989; 20(3):416-28. DOI: 10.1016/s0190-9622(89)70051-7. View

Nistico S, Costanzo A, Saraceno R, Chimenti S . Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis fungoides. Br J Dermatol. 2004; 151(4):877-9. DOI: 10.1111/j.1365-2133.2004.06178.x. View

Piekarz R, Frye R, Turner M, Wright J, Allen S, Kirschbaum M . Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009; 27(32):5410-7. PMC: 2773225. DOI: 10.1200/JCO.2008.21.6150. View

Molina A, Zain J, Arber D, Angelopolou M, ODonnell M, Murata-Collins J . Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol. 2005; 23(25):6163-71. DOI: 10.1200/JCO.2005.02.774. View

Heald P, Glusac E . Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant. J Am Acad Dermatol. 2000; 42(2 Pt 1):283-5. DOI: 10.1016/S0190-9622(00)90140-3. View

Duarte R, Canals C, Onida F, Gabriel I, Arranz R, Arcese W . Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010; 28(29):4492-9. DOI: 10.1200/JCO.2010.29.3241. View

10.

Herbert K, Spencer A, Grigg A, Ryan G, McCormack C, Prince H . Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant. 2004; 34(6):521-5. DOI: 10.1038/sj.bmt.1704641. View

11.

Heald P, Mehlmauer M, Martin A, Crowley C, Yocum R, Reich S . Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003; 49(5):801-15. DOI: 10.1016/s0190-9622(03)01475-0. View

12.

Girardi M, Heald P, Wilson L . The pathogenesis of mycosis fungoides. N Engl J Med. 2004; 350(19):1978-88. DOI: 10.1056/NEJMra032810. View

13.

Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R . Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996; 35(1):69-73. DOI: 10.1016/S0190-9622(96)90499-5. View

14.

Kannangara A, Levitan D, Fleischer Jr A . Six patients with early-stage cutaneous T-cell lymphoma successfully treated with topical 5-fluorouracil. J Drugs Dermatol. 2010; 9(8):1017-8. View

15.

Ponte P, Serrao V, Apetato M . Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J Eur Acad Dermatol Venereol. 2009; 24(6):716-21. DOI: 10.1111/j.1468-3083.2009.03500.x. View

16.

Deeths M, Chapman J, Dellavalle R, Zeng C, Aeling J . Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005; 52(2):275-80. DOI: 10.1016/j.jaad.2004.04.049. View

17.

Lybaek D, Iversen L . Pegylated liposomal doxorubicin in the treatment of mycosis fungoides. Acta Derm Venereol. 2006; 86(6):545-7. DOI: 10.2340/00015555-0133. View

18.

Jones G, Wilson L, Fox-Goguen L . Total skin electron beam radiotherapy for patients who have mycosis fungoides. Hematol Oncol Clin North Am. 2004; 17(6):1421-34. DOI: 10.1016/s0889-8588(03)00108-4. View

19.

Rook A, Heald P . The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995; 9(5):997-1010. View

20.

Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E . Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001; 19(2):376-88. DOI: 10.1200/JCO.2001.19.2.376. View